Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability Is an Independent Determinant of Carotid Intima-Media Thickness in Patients With Type 2 Diabetes

Overview

Journal J Clin Med Res

Specialty General Medicine

Date 2017 Mar 9

PMID 28270891

Citations 8

Authors

Akiko Takenouchi

Ayaka Tsuboi

Kaori Kitaoka

Satomi Minato

Miki Kurata

Keisuke Fukuo

Tsutomu Kazumi

Affiliations

Soon will be listed here.

Abstract

Background: Studies demonstrated that visit-to-visit variability in low-density lipoprotein cholesterol (LDLC) is an independent predictor of cardiovascular events in subjects with coronary artery disease. Whether visit-to-visit variability in LDLC levels affects subclinical atherosclerosis is unknown. This study sought to evaluate the role of visit-to-visit variability in LDLC levels on subclinical atherosclerosis.

Methods: We evaluated 162 type 2 diabetic patients with measurement of carotid intima-media thickness (IMT). Intrapersonal mean and standard deviation (SD) of six measurements of LDLC during 12 months were calculated. Multivariate linear regressions assessed the independent correlates of carotid IMT.

Results: The mean and SD of LDLC were 112 ± 22 and 15 ± 10 mg/dL, respectively, and 43.2% of patients were on hypolipidemic drugs. Age (standardized β = 0.355, P < 0.001), male sex (standardized β = 0.234, P = 0.002) and SD-LDLC (standardized β = 0.201, P = 0.009) emerged as independent determinants of carotid maximum IMT independently of mean LDLC levels, body mass index (BMI), waist circumference, duration and treatment of diabetes, means and SDs of glycemic and other lipid variables, and uses of hypolipidemic and anti-hypertensive medications (R = 0.15). Results did not change when mean IMT was used instead of maximum IMT. After controlling for age and sex, maximum IMT was thicker in patients with the highest compared to those with other three quartiles of SD-LDLC combined (1.14 ± 0.04 (SE) vs. 1.01 ± 0.02 mm, P = 0.01). Independent determinants of SD-LDLC were mean LDLC, use of hypolipidemic drugs, fasting triglyceride and visit-to-visit variability in HbA1c.

Conclusions: Consistency of LDLC levels may be important to subclinical atherosclerosis in real-world patients with type 2 diabetes. It may be important for patients on lipid-lowering drugs to prevent non-compliance.

Citing Articles

Relationship between longitudinal changes in lipid composition and ischemic stroke among hypertensive patients.

Wei C, Huang Y, Yu C World J Clin Cases. 2025; 13(4):95803.

PMID: 39917573 PMC: 11586792. DOI: 10.12998/wjcc.v13.i4.95803.

Long-term visit-to-visit variability in low-density lipoprotein cholesterol is associated with poor cardiovascular and kidney outcomes in patients with primary nephrotic syndrome.

Lai X, Cui Z, Zhang H, Zhang Y, Wang F, Wang X Int Urol Nephrol. 2023; 55(6):1565-1574.

PMID: 36648742 DOI: 10.1007/s11255-023-03467-7.

Lipid variability and risk of microvascular complications in Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: A post hoc analysis.

Nyarko Hukportie D, Li F, Zhou R, Zheng J, Wu X, Zou M J Diabetes. 2022; 14(6):365-376.

PMID: 35668633 PMC: 9366577. DOI: 10.1111/1753-0407.13273.

Association between Variability of Metabolic Risk Factors and Cardiometabolic Outcomes.

Park M, Choi K Diabetes Metab J. 2022; 46(1):49-62.

PMID: 35135078 PMC: 8831817. DOI: 10.4093/dmj.2021.0316.

Visit-to-visit variability in albuminuria predicts renal function deterioration in patients with type 2 diabetes.

Lin C, Lai Y, Chang T, Jiang Y, Chang Y, Chuang L J Diabetes Investig. 2022; 13(6):1021-1029.

PMID: 35100497 PMC: 9153848. DOI: 10.1111/jdi.13761.

References

FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K . Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53(6):982-92. DOI: 10.1053/j.ajkd.2008.12.034. View

Takenouchi A, Tsuboi A, Terazawa-Watanabe M, Kurata M, Fukuo K, Kazumi T . Direct association of visit-to-visit HbA1c variation with annual decline in estimated glomerular filtration rate in patients with type 2 diabetes. J Diabetes Metab Disord. 2015; 14:69. PMC: 4570746. DOI: 10.1186/s40200-015-0201-y. View

Boey E, Gay G, Poh K, Yeo T, Tan H, Lee C . Visit-to-visit variability in LDL- and HDL-cholesterol is associated with adverse events after ST-segment elevation myocardial infarction: A 5-year follow-up study. Atherosclerosis. 2015; 244:86-92. DOI: 10.1016/j.atherosclerosis.2015.10.110. View

Gordts P, Nock R, Son N, Ramms B, Lew I, Gonzales J . ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest. 2016; 126(8):2855-66. PMC: 4966320. DOI: 10.1172/JCI86610. View

Kleiger R, Miller J, BIGGER Jr J, MOSS A . Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987; 59(4):256-62. DOI: 10.1016/0002-9149(87)90795-8. View

. (9) Microvascular complications and foot care. Diabetes Care. 2014; 38 Suppl:S58-66. DOI: 10.2337/dc15-S012. View

Bangalore S, Breazna A, DeMicco D, Wun C, Messerli F . Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial. J Am Coll Cardiol. 2015; 65(15):1539-48. DOI: 10.1016/j.jacc.2015.02.017. View

Giugliano R, Desai N, Kohli P, Rogers W, Somaratne R, Huang F . Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase.... Lancet. 2012; 380(9858):2007-17. PMC: 4347805. DOI: 10.1016/S0140-6736(12)61770-X. View

10.

Yanase T, Nasu S, Mukuta Y, Shimizu Y, Nishihara T, Okabe T . Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope. Am J Hypertens. 2006; 19(12):1206-12. DOI: 10.1016/j.amjhyper.2006.05.010. View

11.

Okada H, Fukui M, Tanaka M, Inada S, Mineoka Y, Nakanishi N . Visit-to-visit variability in systolic blood pressure is correlated with diabetic nephropathy and atherosclerosis in patients with type 2 diabetes. Atherosclerosis. 2011; 220(1):155-9. DOI: 10.1016/j.atherosclerosis.2011.10.033. View

12.

Hata J, Arima H, Rothwell P, Woodward M, Zoungas S, Anderson C . Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation. 2013; 128(12):1325-34. DOI: 10.1161/CIRCULATIONAHA.113.002717. View

13.

Mancini G, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J . Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016; 32(7 Suppl):S35-65. DOI: 10.1016/j.cjca.2016.01.003. View

14.

Malik M, Camm A, Janse M, Julian D, Frangin G, Schwartz P . Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). J Am Coll Cardiol. 2000; 35(5):1263-75. DOI: 10.1016/s0735-1097(00)00571-4. View

15.

McMullan C, Lambers Heerspink H, Parving H, Dwyer J, Forman J, de Zeeuw D . Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. Am J Kidney Dis. 2014; 64(5):714-22. DOI: 10.1053/j.ajkd.2014.06.008. View

16.

Levey A, de Jong P, Coresh J, El Nahas M, Astor B, Matsushita K . The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2010; 80(1):17-28. DOI: 10.1038/ki.2010.483. View

17.

Baber U, Halperin J . Variability in low-density lipoprotein cholesterol and cardiovascular risk: should consistency be a new target?. J Am Coll Cardiol. 2015; 65(15):1549-51. DOI: 10.1016/j.jacc.2015.02.048. View

18.

Xhignesse M, Kessling A, Davignon J, Sing C . Sources of variation in plasma lipid and lipoprotein traits in a sample selected for health. Am J Epidemiol. 1999; 150(11):1229-37. DOI: 10.1093/oxfordjournals.aje.a009950. View

19.

Mann D, Glazer N, Winter M, Paasche-Orlow M, Muntner P, Shimbo D . A pilot study identifying statin nonadherence with visit-to-visit variability of low-density lipoprotein cholesterol. Am J Cardiol. 2013; 111(10):1437-42. PMC: 3644321. DOI: 10.1016/j.amjcard.2013.01.297. View

20.

Hirakawa Y, Arima H, Zoungas S, Ninomiya T, Cooper M, Hamet P . Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014; 37(8):2359-65. DOI: 10.2337/dc14-0199. View